{
    "2019-12-05": [
        [
            {
                "time": "2018-12-05",
                "original_text": "格隆汇港股聚焦(12.5)︱融创中国前11月合同销售额突破5000亿元招商证券11月母公司净利润增23.8%至5.51亿元",
                "features": {
                    "keywords": [
                        "融创中国",
                        "合同销售额",
                        "5000亿元",
                        "招商证券",
                        "净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "房地产",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "复星医药(02196)用于肾病透析患者高磷血症的Tenapanor片获临床试验注册审评受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "Tenapanor片",
                        "肾病",
                        "高磷血症",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "复星医药(600196.SH)：Tenapanor片用于终末期肾病透析患者高磷血症治疗获临床试验注册审评受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "Tenapanor片",
                        "终末期肾病",
                        "高磷血症",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "复星医药：控股子公司获药品临床试验申请受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "控股子公司",
                        "药品",
                        "临床试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "和睦家：将利用资本市场加速医院和科室建设",
                "features": {
                    "keywords": [
                        "和睦家",
                        "资本市场",
                        "医院建设",
                        "科室建设"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "智通港股通持股分析|12月4日",
                "features": {
                    "keywords": [
                        "智通港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "“后复星时代”的和睦家 非公医疗仍面临多重难题",
                "features": {
                    "keywords": [
                        "后复星时代",
                        "和睦家",
                        "非公医疗",
                        "难题"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}